CEACAM-1a regulates graft-versus-host-disease after allogeneic HSCT
CEACAM-1a 调节同种异体 HSCT 后的移植物抗宿主病
基本信息
- 批准号:7851208
- 负责人:
- 金额:$ 87.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAffectAgonistAllogeneic Bone Marrow TransplantationAllogenicAntibodiesAttenuatedCarcinoembryonic AntigenCell Adhesion MoleculesColitisComplicationDevelopmentDifferentiation and GrowthDiseaseEndotheliumEpitheliumFamilyGene Expression ProfilingGlycoproteinsGraft-Versus-Tumor InductionHematologic NeoplasmsHematopoietic Stem Cell TransplantationHomingIL2RA geneImmune responseInfectionInfiltrationInflammationIntegral Membrane ProteinIntegrinsIntestinal Graft Versus Host DiseaseIntestinesLarge IntestineLeadLeukocytesMalignant - descriptorMalignant NeoplasmsMediatingMicroarray AnalysisModelingMolecularMusNon-MalignantOrganOutcomePrevention strategyProphylactic treatmentPublishingRegulationRegulatory T-LymphocyteRoleSELL geneSignal TransductionSmall IntestinesT-LymphocyteTestingTransplant Recipientscancer cellcarcinoembryonic antigen-related cell adhesion moleculesclinically relevantdisorder preventionefficacy testinggraft vs host diseaseimprintimprovedmortalitymouse modelnovel strategiestraffickingtumor growth
项目摘要
Carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM-1) is a
transmembrane protein found on leukocytes, endothelium, and epithelium. Its activation can
attenuate colitis in murine models. Microarray analysis revealed that CEACAM-1 is increased in
the small bowel during intestinal graft-versus-host-disease (GVHD). We studied the role of
CEACAM-1 in mouse models for allogeneic bone marrow transplantation. We found that
CEACAM-1-/- donor T cells caused significantly more GVHD (p<0.05), while CEACAM-1-Tg
donor T cells caused significantly less GVHD (p<0.01). Administration of a CEACAM-1 agonistic
antibody CC1 also significantly attenuated GVHD (p<0.01) Histopathological analysis revealed
significantly increased GVHD of the large bowel in recipients of CEACAM-1-/- T cells (p<0.05),
while recipients of CEACAM-1-Tg T cells had decreased GVHD in all organs (p<0.01). We
performed an extensive analysis and found that alloactivated CEACAM-1-/- T cells (a) have
increased CD25 and decreased CD62L expression (b) have increased expression of the gut-
homing integrin ¿4¿7 (LPAM) and (c) preferentially infiltrate the intestines, while CEACAM-1-Tg
T cells (d) have decreased infiltration of all organs.
Therefore the major hypothesis of this application is: CEACAM-1 is an important
negative regulator of donor T cells during GVHD. We will test the following specific
hypotheses: (1) CEACAM-1 regulates tumor growth and the graft-versus-tumor activity; (2)
CEACAM-1 regulates alloreactive T cell trafficking and integrin ¿4¿7 expression; (3) CEACAM-1
regulates DC-mediated imprinting of gut-specific homing of alloreactive T cells; (4) CEACAM-1
regulates T cell polarization toward the Th1, Th2, Th17, and regulatory T cells; and (5) the
administration of the CEACAM-1 agonist CC1 can ameliorate GVHD.
癌胚抗原相关的细胞粘附分子1(CECAM-1)是一个
在白细胞,内皮和上皮上发现的跨膜蛋白。它的激活可以
在鼠模型中衰减结肠炎。微阵列分析表明,CEACAM-1在
肠道移植物抗疾病(GVHD)期间的小肠。我们研究了
同种异体骨髓移植的小鼠模型中的CEACAM-1。我们发现
CEACAM-1 - / - 供体T细胞引起更大的GVHD(P <0.05),而CEACAM-1-TG
供体T细胞引起的GVHD明显较小(P <0.01)。 CEACAM-1激动剂的管理
抗体CC1还显着减弱了GVHD(P <0.01)的组织病理学分析显示
在CEACAM-1 - / - T细胞受体中,大肠的GVHD显着增加(P <0.05),
尽管CEACAM-1-TG T细胞的受体在所有器官中均恶化GVHD(p <0.01)。我们
进行了广泛的分析,发现同种活化的CEACAM-1 - / - T细胞(a)具有
CD25增加和CD62L表达增加(B)的表达增加
归居整联蛋白€4¿7(LPAM)和(c)优先渗入肠道,而CEACAM-1-TG
T细胞(d)的所有器官浸润改善。
因此,该应用的主要假设是:CEACAM-1是重要的
GVHD期间供体T细胞的负调节剂。我们将测试以下特定
假设:(1)CEACAM-1调节肿瘤生长和移植物肿瘤活性; (2)
CEACAM-1调节同种反应性T细胞运输和整联蛋白»4€7表达; (3)CEACAM-1
调节DC介导的同种异体T细胞的肠道特异性归巢的印迹; (4)CEACAM-1
调节T细胞极化向Th1,Th2,Th17和调节性T细胞。 (5)
CEACAM-1激动剂CC1的给药可以改善GVHD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcel R M van den Brink其他文献
A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation
- DOI:
10.1182/blood-2022-162386 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Doris M Ponce;Jonathan U Peled;Bindu Tejura;Christopher Ford;Marcel R M van den Brink;Mary Jane Lombardo;Satyajit Kosuri;Nandita Khera;Zachariah Defilipp;Lisa von Moltke - 通讯作者:
Lisa von Moltke
Marcel R M van den Brink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marcel R M van den Brink', 18)}}的其他基金
The role of the intestinal microbiome in cancer immunotherapy
肠道微生物组在癌症免疫治疗中的作用
- 批准号:
10738072 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
9762469 - 财政年份:2019
- 资助金额:
$ 87.68万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
10417210 - 财政年份:2019
- 资助金额:
$ 87.68万 - 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
- 批准号:
10179457 - 财政年份:2019
- 资助金额:
$ 87.68万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10374029 - 财政年份:2018
- 资助金额:
$ 87.68万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10369479 - 财政年份:2018
- 资助金额:
$ 87.68万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
9899952 - 财政年份:2018
- 资助金额:
$ 87.68万 - 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
- 批准号:
10524114 - 财政年份:2018
- 资助金额:
$ 87.68万 - 项目类别:
Endothelial cells regulate immune reconstitution after hematopoietic stem cell transplantation
内皮细胞调节造血干细胞移植后的免疫重建
- 批准号:
10357767 - 财政年份:2018
- 资助金额:
$ 87.68万 - 项目类别:
Project 2: Thymic and peripheral Aspects of T cell Aging and Rejuvenation
项目 2:T 细胞衰老和再生的胸腺和外周方面
- 批准号:
10226922 - 财政年份:2017
- 资助金额:
$ 87.68万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:82101697
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Enteric Glia as a Possible Target for Symptom Relief in Endometriosis
肠胶质细胞作为缓解子宫内膜异位症症状的可能目标
- 批准号:
10625609 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别:
Probing Mechanisms of Polycystin-1 Regulation Using Peptide Modulators Designed by Sequence- and Structure-Based Learning
使用基于序列和结构的学习设计的肽调制器探索多囊蛋白-1 调节机制
- 批准号:
10917464 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别:
The Role of Layilin as a Novel Regulator of Platelet Activation and Thromboinflammation
Layilin 作为血小板活化和血栓炎症的新型调节剂的作用
- 批准号:
10638243 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别:
Targeting the Thromboinflammatory Response to Mitigate Bowel Injury in Necrotizing Enterocolitis
靶向血栓炎症反应以减轻坏死性小肠结肠炎的肠道损伤
- 批准号:
10840235 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别:
Investigating the Effects of ADGRB3 Signaling on Incretin-Mediated Insulin Secretion from Pancreatic Beta-Cells
研究 ADGRB3 信号传导对肠促胰素介导的胰腺 β 细胞胰岛素分泌的影响
- 批准号:
10666206 - 财政年份:2023
- 资助金额:
$ 87.68万 - 项目类别: